5-amino-[1,2,4]triazole-1-carbothioic acid benzylamide | 35101-87-2

• 分子结构分类: 有机化合物 - 苯类化合物 - 苯和取代衍生物
• 英文名称: 5-amino-[1,2,4]triazole-1-carbothioic acid benzylamide
• 英文别名: 5-Amino-1-[benzylamino(thiocarbonyl)]-1H-1,2,4-triazole；5-Amino-1-benzylthiocarbamyl-1H-1,2,4-triazol；5-amino-N-benzyl-1,2,4-triazole-1-carbothioamide
• CAS: 35101-87-2
• 化学式: C₁₀H₁₁N₅S
• 分子量: 233.297
• InChiKey: HQDIXAWPWXLCCZ-UHFFFAOYSA-N

计算性质

• 辛醇/水分配系数(LogP)：
  2
• 重原子数：
  16
• 可旋转键数：
  2
• 环数：
  2.0
• sp3杂化的碳原子比例：
  0.1
• 拓扑面积：
  101
• 氢给体数：
  2
• 氢受体数：
  4

反应信息

• 作为产物：
  描述：

  3-氨基-1,2,4-三氮唑 、 异硫氰酸苯甲酯 以 乙腈 为溶剂， 反应 8.0h， 以88%的产率得到5-amino-[1,2,4]triazole-1-carbothioic acid benzylamide
  参考文献：
  名称：

  双取代硫脲衍生物及其在中枢神经系统中的活性：合成与生物学评价

  摘要：

  合成了一系列新的1,2,4-三唑硫脲衍生物。所得化合物的结构差异与异硫氰酸酯的种类（芳基/烷基）直接相关。的1 H NMR，13 C NMR，MS方法被用于获得硫脲衍生物的确认结构。的（分子结构1，17）是由一个X射线分析测定。在行为动物试验中，测试了两种新化合物（8和14）对动物中枢神经系统（CNS）的药理活性。这项工作提出的结果表明，血清素能系统可能参与了8和14的活动。在14的情况下，其活性与内源性阿片样物质系统之间也可能存在联系。测试所有获得的化合物对革兰氏阳性球菌，革兰氏阴性棒的抗菌活性和抗真菌活性。化合物（1，2，5，7，9）显示出对革兰氏阳性球菌显著抑制。对20株标准菌株和30株医院菌株进行了微生物学评估。检查了选定的化合物（1-13）的细胞毒性，抗肿瘤和抗HIV活性。

  DOI：

  10.1016/j.ejmech.2012.07.020

文献信息

• Triazole derivative and pharmaceutical use thereof
  申请人：The Green Cross Corporation

  公开号：US05750545A1

  公开（公告）日：1998-05-12

  An agent for the prophylaxis and treatment of immune-related diseases, in particular, immunosuppressant, an agent for the prophylaxis and treatment of allergic diseases, an agent for the prophylaxis and treatment of eosinophil-related diseases and an eosinophilia inhibitor, comprising, as an active ingredient, a series of triazole derivatives of the following formula (I) ##STR1## or the following formula (III) ##STR2## wherein each symbol is as defined in the specification, or a pharmaceutically acceptable salt thereof. A novel monocyclic or bicyclic triazole derivative. The agent for the prophylaxis and treatment of immune-related diseases, in particular, immunosuppressant, the agent for the prophylaxis and treatment of allergic diseases, the agent for the prophylaxis and treatment of eosinophil-related diseases, the eosinophilia inhibitor and the novel triazole derivative of the present invention all, have superior eosinophilia-inhibitory action and lymphocyte activation-inhibitory action. They are low toxic and persistent in action. They are particularly effective in the treatment of accumulation and activation of eosinophil and lymphocytes, inflammatory respiratory tract diseases, eosinophil-related diseases such as eosinophilia, and immune-related diseases.

  一种用于预防和治疗免疫相关疾病，特别是免疫抑制剂，一种用于预防和治疗过敏疾病的药剂，一种用于预防和治疗嗜酸性粒细胞相关疾病和嗜酸性粒细胞增多抑制剂，包括以下式（I）的一系列三唑衍生物作为活性成分，或以下式（III）的一系列三唑衍生物作为活性成分，其中每个符号如规范中所定义，或其药学上可接受的盐。一种新颖的单环或双环三唑衍生物。本发明的预防和治疗免疫相关疾病，特别是免疫抑制剂，预防和治疗过敏疾病的药剂，预防和治疗嗜酸性粒细胞相关疾病的药剂，嗜酸性粒细胞增多抑制剂和新型三唑衍生物，均具有优越的嗜酸性粒细胞抑制作用和淋巴细胞活化抑制作用。它们毒性低且持久作用。它们在治疗嗜酸性粒细胞和淋巴细胞的积聚和活化、炎症性呼吸道疾病、嗜酸性粒细胞相关疾病如嗜酸性粒细胞增多以及免疫相关疾病方面特别有效。
• TRIAZOLE DERIVATIVE AND PHARMACEUTICAL USE THEREOF
  申请人：THE GREEN CROSS CORPORATION

  公开号：EP0710654A1

  公开（公告）日：1996-05-08

  An agent for the prophylaxis and treatment of immune-related diseases, in particular, immunosuppressant, an agent for the prophylaxis and treatment of allergic diseases, an agent for the prophylaxis and treatment of eosinophil-related diseases and an eosinophilia inhibitor, comprising, as an active ingredient, a series of triazole derivatives of the following formula (I) or the following formula (III) wherein each symbol is as defined in the specification, or a pharmaceutically acceptable salt thereof. A novel monocyclic or bicyclic triazole derivative. The agent for the prophylaxis and treatment of immune-related diseases, in particular, immunosuppressant, the agent for the prophylaxis and treatment of allergic diseases, the agent for the prophylaxis and treatment of eosinophil-related diseases, the eosinophilia inhibitor and the novel triazole derivative of the present invention all have superior eosinophilia-inhibitory action and lymphocyte activation-inhibitory action. They are low toxic and persistent in action. They are particularly effective in the treatment of accumulation and activation of eosinophil and lymphocytes, inflammatory respiratory tract diseases, eosinophil-related diseases such as eosinophilia, and immune-related diseases.

  一种预防和治疗免疫相关疾病的制剂，特别是免疫抑制剂，一种预防和治疗过敏性疾病的制剂，一种预防和治疗嗜酸性粒细胞相关疾病的制剂和一种嗜酸性粒细胞增多抑制剂，其活性成分包括下式（I）的一系列三唑衍生物 或下式（III） 其中各符号如说明书中所定义，或其药学上可接受的盐。一种新型单环或双环三唑衍生物。本发明的预防和治疗免疫相关疾病的制剂，特别是免疫抑制剂、预防和治疗过敏性疾病的制剂、预防和治疗嗜酸性粒细胞相关疾病的制剂、嗜酸性粒细胞抑制剂和新型三唑衍生物都具有优异的嗜酸性粒细胞抑制作用和淋巴细胞活化抑制作用。它们毒性低，作用持久。它们对治疗嗜酸性粒细胞和淋巴细胞的积聚和活化、呼吸道炎症性疾病、嗜酸性粒细胞相关疾病（如嗜酸性粒细胞增多症）以及免疫相关疾病特别有效。
• Synthesis and Pharmacological Activity of Triazole Derivatives Inhibiting Eosinophilia
  作者：Youichiro Naito、Fumihiko Akahoshi、Shinji Takeda、Takehiro Okada、Masahiko Kajii、Hiroko Nishimura、Masanori Sugiura、Chikara Fukaya、Yoshio Kagitani

  DOI：10.1021/jm9507993

  日期：1996.1.1

  In order to develop novel antiasthmatic agents based on a new mechanism of action, a series of 3-substituted 5-amino-1-[(methylamino)(thiocarbonyl)]-1H-1,2,4-triazole derivatives were synthesized and evaluated in a model in which eosinophilia was induced in the ah-way through intravenous (iv) injection of Sephadex particles on days 0, 2, and 5. After screening of several hundred derivatives, we finally identified the highly potent eosinophilia inhibitor 5-amino-3-(4-chlorophenyl)-1-[(methylamino)(thiocarbonyl)]-1H-triazole (23c, GCC-AP0341), which had ID50 values of 0.3 and 0.07 mg/kg when administered orally (os) and intraperitoneally tip), respectively. This compound showed complete inhibition of the hypersensitivity induced by ascaris inhalation at an ip dose of 1 mg/kg as well as low toxicity, with an LD(50) value of > 2.0 g/kg in mice. Extensive study of its mechanism of action revealed that 23c inhibited eosinophil survival induced by interleukin-5 (IL-5), but had little or no effect on leukotriene D-4 (LTD(4)) or platelet-activating factor (PAF)-induced responses. Taken together, these results suggest 23e as a novel candidate for the treatment of chronic asthma. Further studies are now underway.
• Disubstituted thiourea derivatives and their activity on CNS: Synthesis and biological evaluation
  作者：Joanna Stefanska、Daniel Szulczyk、Anna E. Koziol、Barbara Miroslaw、Ewa Kedzierska、Sylwia Fidecka、Bernardetta Busonera、Giuseppina Sanna、Gabriele Giliberti、Paolo La Colla、Marta Struga

  DOI：10.1016/j.ejmech.2012.07.020

  日期：2012.9

  series of new thiourea derivatives of 1,2,4-triazole have been synthesized. The difference in structures of obtained compounds are directly connected with the kind of isothiocyanate (aryl/alkyl). The 1H NMR, 13C NMR, MS methods were used to confirm structures of obtained thiourea derivatives. The molecular structure of (1, 17) was determined by an X-ray analysis. Two of the new compounds (8 and 14)

  合成了一系列新的1,2,4-三唑硫脲衍生物。所得化合物的结构差异与异硫氰酸酯的种类（芳基/烷基）直接相关。的1 H NMR，13 C NMR，MS方法被用于获得硫脲衍生物的确认结构。的（分子结构1，17）是由一个X射线分析测定。在行为动物试验中，测试了两种新化合物（8和14）对动物中枢神经系统（CNS）的药理活性。这项工作提出的结果表明，血清素能系统可能参与了8和14的活动。在14的情况下，其活性与内源性阿片样物质系统之间也可能存在联系。测试所有获得的化合物对革兰氏阳性球菌，革兰氏阴性棒的抗菌活性和抗真菌活性。化合物（1，2，5，7，9）显示出对革兰氏阳性球菌显著抑制。对20株标准菌株和30株医院菌株进行了微生物学评估。检查了选定的化合物（1-13）的细胞毒性，抗肿瘤和抗HIV活性。